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Key Points
•DIAPH1-related disor-
der has a bilineage he-
matological phenotype of
macrothrombocytopenia
and neutropenia associ-
ated with hearing loss.
• Eltrombopag increased
proplatelet formation
from cultured DIAPH1-
related disorder mega-
karyocytes and improved
platelet counts in vivo.
Introduction
The heritable thrombocytopenias (HTs) are genetically heterogeneous rare disorders in which
reduced circulating platelet levels may be associated with nonhematological features.1,2 Among
recently discovered HTs, DIAPH1-related disorder (D-RD; OMIM #124900) was initially reported in
2 pedigrees with macrothrombocytopenia and hearing loss. This phenotype segregated with a
heterozygous p.R1213* variant in DIAPH1, which encodes the cytoskeletal regulator diaphanous
homolog 1 (DIAPH1).3 This predicted truncation of the DIAPH1 C terminus diaphanous autoregulatory
domain (DAD) and was proposed to confer gain-of-function, resulting in megakaryocyte (MK)
cytoskeletal dysregulation and impaired proplatelet formation.3 Macrothrombocytopenia and
hearing loss have subsequently been reported in further isolated pedigrees with DAD DIAPH1
variants,4-6 suggesting that D-RD is a distinct syndromic HT. However, other descriptions of similar
DIAPH1 variants include hearing loss but not hematological findings.7,8
To provide a full phenotypic description of D-RD and the relationship with different DIAPH1
variants, we report detailed hematological findings from 5 D-RD pedigrees, including the in vitro
response and clinical outcome of treatment with the thrombopoietin (TPO) receptor agonist
eltrombopag.
Case description
The 5 pedigrees consist of 16 available cases with heterozygous DIAPH1 variants within the DAD
(10 males, current ages 2-78 years; Figure 1A). Cases A-2, A-3, A-5, D-7, and E-3 (all with
p.R1213*) have already been partially reported by us.3,6 Pedigrees B and C are unreported.
Abnormal bleeding was reported in 6 D-RD cases and was predominantly mild and mucocutaneous
(Figure 1B). Three D-RD cases had previously received prophylactic platelet transfusions to prevent
surgical or obstetric bleeding. The 3 D-RD cases from pedigree E had multiple hospital visits with
respiratory tract or cutaneous infections. Bilateral sensorineural hearing loss was detected at
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Figure 1. Variants in DIAPH1 associated with D-RD. (A) Pedigree diagrams demonstrating cosegregation of the DIAPH1 variants with sensorineural hearing impairment
(black shading) and hematological abnormalities (red shading) in 5 pedigrees. The open symbols indicate unaffected pedigree members. The gray symbols indicate pedigree
members with no data available. *Index cases. (B) Annotation of the 16 D-RD cases with Human Phenotype Ontology terms for bleeding symptoms. Red shading indicates the
presence of the bleeding symptom. Gray shading indicates that a symptom was not applicable due to patient age or sex. (C) Representative May-Gru¨nwald-Giemsa–stained
peripheral blood smears from D-RD cases A-2, B-4, and C-9 representing each of the 3 observed DIAPH1 variants. Original magnification 340. (D) Hematoxylin and
eosin–stained bone marrow biopsy from D-RD case A-2 (R1213*). Granulopoiesis was reduced, with few examples of mature neutrophils. MKs were normal in number but
generally small, with hypolobated nuclei (arrows). Original magnification 3100. V, variant DIAPH1 alleles; 1, wild-type DIAPH1 alleles.
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Figure 2. Detailed evaluation of D-RD cases. (A) Schematic representation of DIAPH1 and DIAPH1 protein divided into functional domains, including the DAD
near the C terminus. The expanded box shows the wild-type DAD amino acid sequence; the positions of the regulatory RRKR and MDxLLExL sequence motifs are
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neonatal screening or in early childhood in all cases and
progressed through childhood. Twelve cases required hearing
aids, and 1 case underwent successful cochlear implantation.
There were no other consistently reported clinical features.
Methods
Cases were identified through the National Institute for Health
Research BioResource–Rare Diseases (pedigrees A-C; UK REC
13/EE/0325) and Functional and Molecular Characterization of
Patients with Inherited Platelet Disorders (pedigrees D-E; Centro
Regional de Hemodonacio´n, Universidad de Murcia) programs.
Phenotype collection and high-throughput sequencing were as
reported previously.6,9,10
Results and discussion
All 16 D-RD cases displayed mild thrombocytopenia on $1 occasion
(median platelet count, 111 3 109/L; range, 13-209 3 109/L) and
enlarged platelets (median mean platelet volume, 12.7 fl; range, 9.3-
19.8). Eleven cases also displayed neutropenia on$1 occasion (median
neutrophil count, 1.33 3 109/L; range, 0.50-4.30) (supplemental
Table 1). There were no other morphological abnormalities by light
microscopy (Figure 1C). Bonemarrow biopsies from cases A-2 and D-3
revealed a normal distribution of cells but reduced granulopoiesis in
case A-2. MKs were present in normal numbers but were small with
hypolobated nuclei (Figure 1D). Neutrophil adhesion, degranulation,
reactive oxygen species generation, and extracellular trap formationwere
the same in D-RD cases with the p.R1213X and p.A1210GfsTer31
DIAPH1 variants as controls (supplemental Table 2). There were no
consistent abnormalities in immunoglobulin concentrations, lymphocyte
subset numbers, or lymphocyte proliferation responses (supplemental
Table 2). There was no consistent red cell phenotype.
The DIAPH1 variants included the previously reported p.R1213*3,6
and the unreported p.A1210GfsTer31 arising from the dinucleotide
deletion DIAPH1 c.3771_3772delAG (pedigree B). Cases from
pedigree C harbored an unreported inversion with breakpoints in
DIAPH1 introns 26 and 27, predicting in-frame skipping of exon 27
(p.E1192_Q1220del). Consistent with this, a platelet complemen-
tary DNA amplicon corresponding to DIAPH1 exons 26-28 was
smaller in pedigree C compared with controls and did not contain
exon 27 (supplemental Figure 1). All of the DIAPH1 variants predict
truncation within the DIAPH1 DAD (Figure 2A), resulting in loss
of the RRKR motif and, for p.E1192_Q1220del (pedigree C), also
the MDxLLExL motif. These conserved regulatory sequences within
the DAD mediate DIAPH1 autoinhibition by competitive binding
at the Rho GTPase activation site in the GBD/FH3 domain.11
Cases from pedigree C had more bleeding symptoms and the
lowest overall platelet counts in the cohort, suggesting a relation-
ship between the extent of the DAD truncation and phenotype.
To evaluate the safety of the TPO receptor agonist eltrombopag
(Novartis, Frimley, United Kingdom) as a potential therapy to increase
platelet count in D-RD, we first evaluated its effect on TPO receptor
signaling in D-RD platelets. In platelets from healthy controls,
eltrombopag activates TPO receptor signaling pathways to a lesser
extent than TPO and does not enhance agonist-mediated activa-
tion.12 In keeping with this, immune thrombocytopenia patients
receiving eltrombopag show no increase in platelet activation in vivo.13
In platelets from D-RD cases with all 3 variants, clinically relevant
eltrombopag concentrations stimulated only weak phosphorylation of
pJAK2Y1007/1008 and pSTAT5a/bY694 comparedwith TPO (Figure 2B).
This response was similar in healthy controls and indicated no effect of
the DIAPH1 variants on the TPO receptor pathway in platelets.
We reported previously that blood cell–derived CD341 MKs from
case A-2 with the DIAPH1 p.R1213* variant displayed abnormal
clustering and reduced proplatelet production, as well as abundant
and disorganized actin, when cultured with TPO.3 This finding
was similar in MKs from cases B-4 (p.A1210GfsTer31) and C-9
(p.E1192_Q1220del) (supplemental Figure 2), supporting a
common effect from the different DAD variants (Figure 2C-D). For
all 3 cases, there was a trend toward reduced MK clustering and
increased proplatelet production after culture of MKs with
eltrombopag instead of TPO and further improvement after culture
with TPO plus eltrombopag (Figure 2C-D).
We monitored the clinical effect of eltrombopag in case C-9
(DIAPH1 p.E1192_Q1220del) who, unrelated to D-RD, required
right hip arthroplasty. However, because of previous platelet
transfusions, case C-9 had multiple anti-HLA immunoglobulin G
alloantibodies and platelet refractoriness. Eltrombopag (50 mg) was
administered once daily from day 229 before surgery, which was
increased to 75 mg once daily from day 29 until day 21. The
platelet count, which was determined using the PLT-F detection
Figure 2. (continued) indicated by red shading. The predicted impact of the variants associated with D-RD is shown compared with the reference sequence. The
abnormal C terminus amino acid sequence predicted from the p.A1210GfsTer31 variant is indicated in red type. The position of exon 27 residues that are absent
with the p.E1192_Q1220del variant is indicated by the dashed line. *Premature stop codon. (B) Representative immunoblot using monoclonal antibodies
recognizing p-STAT5a/bY694, total STAT5a/b, pJAK21007/1008, and total JAK2 of lysates from case A-2 and control platelets stimulated with eltrombopag (0-30 mM)
or TPO (100 ng/mL) (left panels). Bar graphs of the ratio of phosphorylated/total densitometry signal of 3 D-RD cases (A-2, B-4, and C-9) combined show that
eltrombopag causes markedly reduced STAT5a/b and JAK2 phosphorylation compared with TPO and that the extent of phosphorylation in D-RD platelets is
the same as controls (middle and right panels). The data are representative of 3 independent experiments expressed as mean 6 standard error of the mean.
(C) Representative immunofluorescence confocal microscopy images (case A-2 and control) of differentiated peripheral blood–derived CD341 MKs at day 12 of
culture, visualized using anti-integrin b3 (green; CD61) and phalloidin (red; F-actin) staining. In the presence of TPO, D-RD MKs show abnormal clustering, reduced
proplatelet formation, and abnormal distribution of F-actin when compared with controls. Reduced proplatelet formation and cluster formation are partially rescued
in culture conditions containing eltrombopag (EP). (D) Corresponding bar graphs of aggregate data from duplicate MK-differentiation experiments from 3 unrelated
healthy controls and cases A-2, B-4, and C-9, with each of the 3 D-RD variants cultured with TPO (5 mM), EP (3 mM), or TPO (2.5 mM) 1 EP (2 mM). Data are
expressed as mean and standard error of the mean of the percentage of all cultured MKs that associate in clusters and the percentage that are forming proplatelet
extensions, as specified in supplemental Methods. (E) Time course of the hematological response to oral eltrombopag administered to case C-9 before elective hip
arthroplasty at day 0. Platelet counts were determined using a Sysmex XN analyzer using the fluorescence end point. ***P , .0001, **P , .001, *P , .05, 1-way
analysis of variance. ns, not significant.
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end point (XN-Series analyzer; Sysmex, Kobe, Japan), increased
from a baseline of 29 3 109/L to 72 3 109/L on day 21 before
surgery (Figure 2E). The patient also received tranexamic acid for
72 hours from the start of surgery but not platelet transfusion.
Hemostasis was satisfactory (total estimated blood loss 500 mL vs
493 mL for controls undergoing similar surgery14), and there were
no adverse events.
This largest reported series of 16 cases illustrates that D-RD is
a dominant disorder characterized by macrothrombocytopenia,
neutropenia, and hearing loss. This analysis revealed no defects
in neutrophil function, and no lymphoid or red cell abnormalities.
Although neutropenia potentially accounted for the recurrent
infections observed in 1 D-RD pedigree (E), clinical immunodeficiency
was absent in the other cases. No cases had renal disease, cataracts,
or neutrophil inclusions, distinguishing D-RD from MYH9-related
disorder in which there may also be macrothrombocytopenia
and hearing loss.15-17 The D-RD phenotype was associated with
chain truncation variants close to the DIAPH1 C terminus, resulting in
loss of conserved regions responsible for autoinhibitory interactions
within the DIAPH1 protein.11 This suggests a distinct molecular
pathogenesis for D-RD, arising from a gain-of-function effect.
This report also illustrates that eltrombopag partly rescues
defective proplatelet formation in D-RD MKs cultured in vitro but
that TPO receptor signaling responses in D-RD platelets are
unaltered. We provide proof of concept that, similar to in MYH9-
related disorder,18,19 short-term eltrombopag may allow temporary
correction of platelet counts in D-RD cases before surgery, enabling
avoidance of platelet transfusion.
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